Diagonal Bio publishes interim report for the second quarter of 2025

Summary of the interim report for the second quarter of 2025

2025-04-01 — 2025-06-30 (April — June 2025)

• Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributed with 284 KSEK

(284 KSEK), and other operating income amounted to 0 KSEK (0 KSEK).

• The net loss amounted to -2 599 KSEK (-3 118 KSEK).
• Operating profit per net weighted average share amounted to -0.002 SEK (-0.01 SEK).
• Cash flow during the second quarter amounted to 1 765 KSEK (2 302 KSEK).
• Cash and cash equivalents at the end of the period amounted to 2 739 KSEK (4 158 KSEK).

Significant events during the second quarter of 2025

• April 25, Diagonal Bio announced that the Company would transition its news distribution service from Cision News to Modular Finance (MFN), starting April 28.
• May 5, Diagonal Bio announced the appointment of Anders Wallseth as Senior Commercial Advisor. Wallseth’s appointment represents a significant step forward in accelerating the commercial launch and market growth of Diagonal Bio’s LAMPlify® system.
• May 16, Diagonal Bio announced that the Company had agreed on pre-subscription and underwriting commitments corresponding to 100 percent of the warrants of series TO 2.
• June 4, Diagonal Bio announced the start of the exercise period for the warrants of series TO 2, which were issued in connection with the Company’s rights issue of units In January/February 2025.
• June 9, Diagonal Bio announced that Svea Bank AB had informed the Company that it had exercised all its warrants of series TO 2, resulting in an investment of SEK 0.5 million.
• June 11, Diagonal Bio provided an update on the progress of LAMPlify® commercial pilots.
• June 17, Diagonal Bio announced the positive progress of a test for the bacteria Streptococcusequi subs. Equi, which causes strangles (“kvarka” in Swedish). This new test is designed to work with the existing LAMPlify equine respiratory virus panel to provide broader coverage of threats to equine health.
• June 17, Diagonal Bio announced that Stig Aune, a large shareholder in the Company, had informed the Company that he had exercised warrants of series TO 2 to an amount of SEK 0.14 million.
• June 19, Diagonal Bio announced that the exercise of warrants of series TO 2 had an outcome with an exercise rate of 59.3 percent, and thus, that the underwriting commitment would be activated to 40.7 percent.
• June 25, Diagonal Bio announced that the Board of Directors had resolved on a directed issue to the underwriters in the warrant exercise. The directed issue covered both the activated underwriting and the compensation for the underwriters, in accordance with the underwriting agreements.

Significant events since 30 June 2025

• July 7, Diagonal Bio announced that the Company had filed a patent application with the Swedish Intellectual Property Office (PRV), covering a novel computational method that significantly improves the design of LAMP primers – a critical component in molecular analysis.
• August 20, Diagonal Bio announced that the Company had received a confirmation from the Japanese Patent Office that the patent application regarding “A method of measuring the pH of a sample” (no.: JP7655939) has been granted in Japan.

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on August 22, 2025, at 08:00 CET.

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com

About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.